'김갑성' 기자의 전체기사
-
Health In Tech to Host Annual Meeting of Stockholders
STUART, Fla., Sept. 11, 2025 -- Health In Tech (Nasdaq: HIT) will host its 2025 Annual Stockholder Meeting on Friday, October 3, 2025, at 10:00 AM ET live via virtual webcast. To participate in the Annual Stockholders Meeting, stockholders should visit www.cleartrustonline.com/HIT or the Company's Investor Relations site at https://healthintech.investorroom.com/ under "News & Events," and enter the 12-digit control number found in the proxy materials. Guests may also access the Annual Shareholders Meeting in listen-only mode. No control number is re
- 김갑성 기자
- 2025-09-11 04:30
-
메타볼론, 차이나 카두리 바이오뱅크와 협력해 정밀의료 발전 추진
멀티오믹스 연구 통해 생활습관, 환경, 사회경제적, 유전적 요인이 일반 질환 형성에 얼마나 중요한 역할을 하는지 규명할 예정 모리스빌, 노스캐롤라이나주, 2025년 9월 11일 -- 광범위한 생명과학 연구, 진단, 치료제 개발 및 정밀의학 응용 발전에 앞장서는 대사체학(metabolomics) 솔루션 제공 분야 글로벌 선도기업 메타볼론(Metabolon)이 9일 차이나 카두리 바이오뱅크(China Kadoorie Biobank, 이하 CKB) 의뢰로 자사의 글로벌 디스커버리 패널™(Global Discovery Panel™)을 활용해 혈장 대사체학 바이오마커를 분석하기로 했다고 밝혔다. CKB는 생활습관과 환경 및 유전적•사회경제적 요인이 일반 질환 형성에 어떻게 중요한 역할을 하는지 조사하는 세계 최대 규모이자 가장 포괄적인 코호트 연구 중 하나다. CKB는 2004년부터 2008년 사이 옥스퍼드 대학교와 베이징 대학교 등이 포함된 중국 내 다양한 파트너 기관이 공동으로 추진해온 장기 협력 프로젝트다. 지금까지 임상 시험과 인구 건강 연구는 주로 백인 유럽인 참가자에 집중된 탓에 다른 인종과 민족 집단의 다양성은 간
- 김갑성 기자
- 2025-09-11 02:51
-
TVM Capital Healthcare Announces First Closing of its USD 150…
SINGAPORE, Sept. 11, 2025 -- TVM Capital Healthcare, a global private equity investor and operator specialized in healthcare growth capital across emerging markets, today announced the first closing of its USD 150 million TVM Healthcare Southeast Asia Fund ("SEA Fund"). The SEA Fund is the third generation of TVM Capital Healthcare funds and builds on the firm's nearly 40 years of global healthcare investment and operator experience, including over 15 years of scaling healthcare companies across the Middle East and Southeast Asia. TVM Capital Healthcare has a strong t
- 김갑성 기자
- 2025-09-11 02:39
-
Three global institutions win million dollar prize for the 2025 An…
[ 메디채널 김갑성 기자 ] Valued at €1 million, it is the world's largest award in the field of vision, recognising work that combines scientific excellence, global impact, and a commitment to equity in eyesight. The Fred Hollows Foundation has restored sight to more than 3 million people in more than 25 countries across Asia, Africa, and Oceania. The Lions Clubs International Foundation (LCIF) has provided eye health services to more than 544 million people in 118 countries, performing over nine million cataract surgeries. The International Agency for the Prevention of Blindness (IAPB) stands o
- 김갑성 기자
- 2025-09-10 23:41
-
Altair and Wichita State University's NIAR Sign MoU to Accelerate…
Collaboration will expand digital twin adoption, empower aerospace startups, and speed up product development and certification processes TROY, Mich., Sept. 10, 2025 -- Altair, a global leader in computational intelligence, and Wichita State University's (WSU) National Institute for Aviation Research (NIAR), one of the world's leading aerospace research institutions, have signed a memorandum of understanding (MoU) to advance innovation across the aerospace and defense industries. "NIAR is a global leader in aerospace research, and this partnership paves the
- 김갑성 기자
- 2025-09-10 23:16
-
Shineco Achieves Mass Production of High-Purity Physical P…
BEIJING, Sept. 10, 2025 -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions conf
- 김갑성 기자
- 2025-09-10 21:30
-
C-Ray Therapeutics Supports Mednovo's Phase III Clinical T…
CHENGDU, China, Sept. 10, 2025 -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive clinical supply and manufacturing partner, C-Ray Therapeutics delivered end-to-end support for this milestone, including technology transfer, clinical batch production, quality release, and logistics. Leveraging China's first fully automated radiopharmaceutical production line built to global cGMP
- 김갑성 기자
- 2025-09-10 21:30
-
Imaging Endpoints Announces Patent Application for AI Revi…
SCOTTSDALE, Ariz., Sept. 10, 2025 -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative AIRC System™ is designed to enhance highly customized IRCs for clinical trials, setting new standards in the industry. Imaging Endpoints is the scientific leader in customizing and optimizing image acquisition and analysis for clinical trials in oncology, with the most sophisticated approac
- 김갑성 기자
- 2025-09-10 21:00
-
LakeShore Biopharma Announces Appointment of Indepen…
BEIJING, Sept. 10, 2025 -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the independent special committee (the "Special Committee") of the Company's board of directors (the "Board"), formed to evaluate and consider the previously announced revised preliminary non-binding proposal letter dated August 26,
- 김갑성 기자
- 2025-09-10 20:10
-
Optain Health Closes $26 Million Series A to Bring Oculomics to…
Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK, Sept. 10, 2025 -- Optain Health, a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the close of an oversubscribed $26 million Series A. The raise was led by global software investor Insight Partners with participation from existing investors. A single, non
- 김갑성 기자
- 2025-09-10 20:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
2025-10-21_TUE
- AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform 23:30
- Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq 23:00
- Stéphane Rolland's Haute Couture to Illuminate the 10th Anniversary of Barcelona Bridal Night 23:00
- JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène 22:00
- AI meets capital: Bizcap welcomes 8fig into its global portfolio to accelerate growth funding 22:00
- Youth Innovation Safeguards Green Heritage: 2025 World Food Forum Youth Action on Green Agri-Heritage Held in Rome 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 03시 00분